

January 22, 2025

Jagsonpal Pharmaceuticals Limited: Ratings withdrawn

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term/short-term – Unallocated Limits	1.80	1.80	[ICRA]BBB(Positive)/ [ICRA]A2; Withdrawn
Total	1.80	1.80	

*Instrument details are provided in Annexure-I

Rationale

ICRA has withdrawn the ratings assigned to the bank facilities of Jagsonpal Pharmaceuticals Limited (JPL) at the company's request, and in accordance with ICRA's policy on withdrawal.

However, ICRA does not have information to suggest that the credit risk has changed since the time the rating was last reviewed. The key rating drivers, Liquidity position, rating sensitivities, key financial indicators have not been captured as the rated instruments are being withdrawn. The previous detailed rating rationale is available at the following link: [Click here](#)

Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Pharmaceuticals Policy on Withdrawal of Credit Ratings
Parent/Group support	Not applicable
Consolidation/Standalone	Standalone

About the company

JPL is a branded formulation company with a key focus on women's healthcare products in the therapeutic areas of gynaecology and orthopaedics. JPL was founded in 1964 by Mr. Jagmohan S Kochhar in Delhi, the company was managed by his son, Mr. Rajpal Kochhar, and his family until FY2022. The company initially had two manufacturing facilities in Faridabad and Rudrapur. In FY2017, JPL sold its Rudrapur facility and closed the Faridabad unit in FY2022. In Q4 FY2022, the promoters sold a majority stake to a Mauritius-based private equity fund. The company has several brands, including Divatrone, Lycored, Metadec, Indocap and Maintene. JPL has acquired a few brands such as Eukroma and Itratop in the dermatology category and Ventiphylline – PD and Tinilox in the paediatric category from YPPL in May 2024. The company is listed on stock exchanges (BSE and NSE).

Status of non-cooperation with previous CRA: Not Applicable

Any other information: None

Rating history for past three years

Instrument	Current (FY2025)				Chronology of rating history for the past 3 years						
	Type	Amount Rated (Rs Crore)	January 22, 2025	FY2025		FY2024		FY2023		FY2022	
				Date	Rating	Date	Rating	Date	Rating	Date	Rating
Unallocated Limits	Long-term/ Short-term	1.80	[ICRA]BBB (Positive)/ [ICRA]A2; Withdrawn	21-Jun-2024	[ICRA]BBB (Positive)/ [ICRA]A2	14-Apr-2023	[ICRA]BBB (Positive)/ [ICRA]A2	10-Oct-2022	[ICRA]BBB (Positive)/ [ICRA]A3+	10-Mar-2022	[ICRA]BBB (Stable)/ [ICRA]A3+
				-	-	-	-	-	-	30-Sep-2021	[ICRA]BBB (Stable)/ [ICRA]A3+

Complexity level of the rated instrument

Instrument	Complexity Indicator
Long-term/ Short-term – Unallocated Limits	Not applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure I: Instrument details

ISIN	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Unallocated	NA	NA	NA	1.80	[ICRA]BBB (Positive)/ [ICRA]A2; Withdrawn

Source: Company

Annexure II: List of entities considered for consolidated analysis – Not Applicable

ANALYST CONTACTS

Shamsher Dewan

91 124 4545 328

shamsherd@icraindia.com

Kinjal Shah

+91 22 6114 3442

Kinjal.shah@icraindia.com

Deepak Jotwani

+91 124 4545 870

Deepak.jotwani@icraindia.com

Uday Kumar

+91 124 4545 867

uday.kumar@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited




Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45



Branches



© Copyright, 2025 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.